nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Scab—Fluorouracil—head and neck cancer	0.0452	0.0458	CcSEcCtD
Apraclonidine—Blepharitis—Hydroxyurea—head and neck cancer	0.0324	0.0329	CcSEcCtD
Apraclonidine—Lacrimation—Fluorouracil—head and neck cancer	0.0244	0.0248	CcSEcCtD
Apraclonidine—Blepharitis—Fluorouracil—head and neck cancer	0.0233	0.0237	CcSEcCtD
Apraclonidine—Photophobia—Vinblastine—head and neck cancer	0.0205	0.0208	CcSEcCtD
Apraclonidine—Lacrimation—Docetaxel—head and neck cancer	0.0176	0.0179	CcSEcCtD
Apraclonidine—Eye irritation—Fluorouracil—head and neck cancer	0.0168	0.0171	CcSEcCtD
Apraclonidine—Parosmia—Docetaxel—head and neck cancer	0.016	0.0162	CcSEcCtD
Apraclonidine—Lacrimation increased—Fluorouracil—head and neck cancer	0.0156	0.0158	CcSEcCtD
Apraclonidine—Inflammation—Fluorouracil—head and neck cancer	0.0148	0.015	CcSEcCtD
Apraclonidine—Dermatitis contact—Fluorouracil—head and neck cancer	0.0142	0.0144	CcSEcCtD
Apraclonidine—Clonidine—CYP1A1—head and neck cancer	0.0141	1	CrCbGaD
Apraclonidine—Face oedema—Hydroxyurea—head and neck cancer	0.014	0.0142	CcSEcCtD
Apraclonidine—Photophobia—Fluorouracil—head and neck cancer	0.0135	0.0137	CcSEcCtD
Apraclonidine—Rhinorrhoea—Docetaxel—head and neck cancer	0.0128	0.013	CcSEcCtD
Apraclonidine—Eye irritation—Docetaxel—head and neck cancer	0.0121	0.0123	CcSEcCtD
Apraclonidine—Lacrimation increased—Docetaxel—head and neck cancer	0.0112	0.0114	CcSEcCtD
Apraclonidine—Infestation NOS—Hydroxyurea—head and neck cancer	0.0112	0.0113	CcSEcCtD
Apraclonidine—Infestation—Hydroxyurea—head and neck cancer	0.0112	0.0113	CcSEcCtD
Apraclonidine—Haemorrhage—Vinblastine—head and neck cancer	0.011	0.0111	CcSEcCtD
Apraclonidine—Pharyngitis—Vinblastine—head and neck cancer	0.0109	0.0111	CcSEcCtD
Apraclonidine—Inflammation—Docetaxel—head and neck cancer	0.0107	0.0108	CcSEcCtD
Apraclonidine—Haemorrhage—Hydroxyurea—head and neck cancer	0.01	0.0102	CcSEcCtD
Apraclonidine—Irritability—Fluorouracil—head and neck cancer	0.00995	0.0101	CcSEcCtD
Apraclonidine—Nasopharyngitis—Fluorouracil—head and neck cancer	0.00932	0.00945	CcSEcCtD
Apraclonidine—Angiopathy—Hydroxyurea—head and neck cancer	0.00909	0.00922	CcSEcCtD
Apraclonidine—Ill-defined disorder—Vinblastine—head and neck cancer	0.00887	0.009	CcSEcCtD
Apraclonidine—Erythema—Hydroxyurea—head and neck cancer	0.00872	0.00884	CcSEcCtD
Apraclonidine—Malaise—Vinblastine—head and neck cancer	0.00862	0.00875	CcSEcCtD
Apraclonidine—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.00809	0.00821	CcSEcCtD
Apraclonidine—Discomfort—Vinblastine—head and neck cancer	0.00804	0.00816	CcSEcCtD
Apraclonidine—Infestation NOS—Fluorouracil—head and neck cancer	0.00803	0.00815	CcSEcCtD
Apraclonidine—Infestation—Fluorouracil—head and neck cancer	0.00803	0.00815	CcSEcCtD
Apraclonidine—Malaise—Hydroxyurea—head and neck cancer	0.00786	0.00798	CcSEcCtD
Apraclonidine—Conjunctivitis—Fluorouracil—head and neck cancer	0.00781	0.00792	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00737	0.00748	CcSEcCtD
Apraclonidine—Discomfort—Hydroxyurea—head and neck cancer	0.00733	0.00744	CcSEcCtD
Apraclonidine—Rhinitis—Fluorouracil—head and neck cancer	0.00723	0.00733	CcSEcCtD
Apraclonidine—Haemorrhage—Fluorouracil—head and neck cancer	0.00721	0.00731	CcSEcCtD
Apraclonidine—Pharyngitis—Fluorouracil—head and neck cancer	0.00716	0.00726	CcSEcCtD
Apraclonidine—Oedema—Hydroxyurea—head and neck cancer	0.00712	0.00722	CcSEcCtD
Apraclonidine—Infection—Hydroxyurea—head and neck cancer	0.00707	0.00717	CcSEcCtD
Apraclonidine—Paraesthesia—Vinblastine—head and neck cancer	0.00701	0.00711	CcSEcCtD
Apraclonidine—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00698	0.00708	CcSEcCtD
Apraclonidine—Skin disorder—Hydroxyurea—head and neck cancer	0.00691	0.00701	CcSEcCtD
Apraclonidine—Nasopharyngitis—Docetaxel—head and neck cancer	0.00673	0.00682	CcSEcCtD
Apraclonidine—Pain—Vinblastine—head and neck cancer	0.00667	0.00677	CcSEcCtD
Apraclonidine—Constipation—Vinblastine—head and neck cancer	0.00667	0.00677	CcSEcCtD
Apraclonidine—Arrhythmia—Fluorouracil—head and neck cancer	0.00644	0.00653	CcSEcCtD
Apraclonidine—Feeling abnormal—Vinblastine—head and neck cancer	0.00643	0.00652	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00638	0.00647	CcSEcCtD
Apraclonidine—Dyspnoea—Hydroxyurea—head and neck cancer	0.00634	0.00644	CcSEcCtD
Apraclonidine—Somnolence—Hydroxyurea—head and neck cancer	0.00633	0.00642	CcSEcCtD
Apraclonidine—Erythema—Fluorouracil—head and neck cancer	0.00628	0.00637	CcSEcCtD
Apraclonidine—Abdominal pain—Vinblastine—head and neck cancer	0.00617	0.00626	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00614	0.00623	CcSEcCtD
Apraclonidine—Fatigue—Hydroxyurea—head and neck cancer	0.00614	0.00622	CcSEcCtD
Apraclonidine—Pain—Hydroxyurea—head and neck cancer	0.00609	0.00617	CcSEcCtD
Apraclonidine—Constipation—Hydroxyurea—head and neck cancer	0.00609	0.00617	CcSEcCtD
Apraclonidine—Vision blurred—Fluorouracil—head and neck cancer	0.00592	0.006	CcSEcCtD
Apraclonidine—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00586	0.00595	CcSEcCtD
Apraclonidine—Infestation—Docetaxel—head and neck cancer	0.0058	0.00588	CcSEcCtD
Apraclonidine—Infestation NOS—Docetaxel—head and neck cancer	0.0058	0.00588	CcSEcCtD
Apraclonidine—Hypersensitivity—Vinblastine—head and neck cancer	0.00575	0.00583	CcSEcCtD
Apraclonidine—Conjunctivitis—Docetaxel—head and neck cancer	0.00563	0.00572	CcSEcCtD
Apraclonidine—Asthenia—Vinblastine—head and neck cancer	0.0056	0.00568	CcSEcCtD
Apraclonidine—Myalgia—Fluorouracil—head and neck cancer	0.00534	0.00542	CcSEcCtD
Apraclonidine—Chest pain—Fluorouracil—head and neck cancer	0.00534	0.00542	CcSEcCtD
Apraclonidine—Diarrhoea—Vinblastine—head and neck cancer	0.00534	0.00542	CcSEcCtD
Apraclonidine—Discomfort—Fluorouracil—head and neck cancer	0.00528	0.00535	CcSEcCtD
Apraclonidine—Hypersensitivity—Hydroxyurea—head and neck cancer	0.00524	0.00532	CcSEcCtD
Apraclonidine—Rhinitis—Docetaxel—head and neck cancer	0.00522	0.00529	CcSEcCtD
Apraclonidine—Haemorrhage—Docetaxel—head and neck cancer	0.0052	0.00528	CcSEcCtD
Apraclonidine—Pharyngitis—Docetaxel—head and neck cancer	0.00516	0.00524	CcSEcCtD
Apraclonidine—Dizziness—Vinblastine—head and neck cancer	0.00516	0.00523	CcSEcCtD
Apraclonidine—Oedema peripheral—Docetaxel—head and neck cancer	0.00513	0.0052	CcSEcCtD
Apraclonidine—Oedema—Fluorouracil—head and neck cancer	0.00512	0.0052	CcSEcCtD
Apraclonidine—Asthenia—Hydroxyurea—head and neck cancer	0.00511	0.00518	CcSEcCtD
Apraclonidine—Infection—Fluorouracil—head and neck cancer	0.00509	0.00516	CcSEcCtD
Apraclonidine—Nervous system disorder—Fluorouracil—head and neck cancer	0.00502	0.0051	CcSEcCtD
Apraclonidine—Visual impairment—Docetaxel—head and neck cancer	0.00501	0.00509	CcSEcCtD
Apraclonidine—Vomiting—Vinblastine—head and neck cancer	0.00496	0.00503	CcSEcCtD
Apraclonidine—Headache—Vinblastine—head and neck cancer	0.00489	0.00496	CcSEcCtD
Apraclonidine—Diarrhoea—Hydroxyurea—head and neck cancer	0.00487	0.00494	CcSEcCtD
Apraclonidine—Eye disorder—Docetaxel—head and neck cancer	0.00486	0.00493	CcSEcCtD
Apraclonidine—Angiopathy—Docetaxel—head and neck cancer	0.00472	0.00479	CcSEcCtD
Apraclonidine—Dizziness—Hydroxyurea—head and neck cancer	0.00471	0.00477	CcSEcCtD
Apraclonidine—Mediastinal disorder—Docetaxel—head and neck cancer	0.00469	0.00476	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.00467	0.00473	CcSEcCtD
Apraclonidine—Arrhythmia—Docetaxel—head and neck cancer	0.00465	0.00472	CcSEcCtD
Apraclonidine—Nausea—Vinblastine—head and neck cancer	0.00464	0.0047	CcSEcCtD
Apraclonidine—Insomnia—Fluorouracil—head and neck cancer	0.00463	0.0047	CcSEcCtD
Apraclonidine—Paraesthesia—Fluorouracil—head and neck cancer	0.0046	0.00467	CcSEcCtD
Apraclonidine—Dyspnoea—Fluorouracil—head and neck cancer	0.00457	0.00463	CcSEcCtD
Apraclonidine—Mental disorder—Docetaxel—head and neck cancer	0.00456	0.00462	CcSEcCtD
Apraclonidine—Somnolence—Fluorouracil—head and neck cancer	0.00455	0.00462	CcSEcCtD
Apraclonidine—Erythema—Docetaxel—head and neck cancer	0.00453	0.00459	CcSEcCtD
Apraclonidine—Vomiting—Hydroxyurea—head and neck cancer	0.00452	0.00459	CcSEcCtD
Apraclonidine—Dermatitis—Hydroxyurea—head and neck cancer	0.00448	0.00455	CcSEcCtD
Apraclonidine—Headache—Hydroxyurea—head and neck cancer	0.00446	0.00452	CcSEcCtD
Apraclonidine—Dysgeusia—Docetaxel—head and neck cancer	0.00444	0.0045	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00442	0.00449	CcSEcCtD
Apraclonidine—Pain—Fluorouracil—head and neck cancer	0.00438	0.00444	CcSEcCtD
Apraclonidine—Nausea—Hydroxyurea—head and neck cancer	0.00423	0.00429	CcSEcCtD
Apraclonidine—Feeling abnormal—Fluorouracil—head and neck cancer	0.00422	0.00428	CcSEcCtD
Apraclonidine—Syncope—Docetaxel—head and neck cancer	0.00406	0.00412	CcSEcCtD
Apraclonidine—Palpitations—Docetaxel—head and neck cancer	0.004	0.00406	CcSEcCtD
Apraclonidine—Chest pain—Docetaxel—head and neck cancer	0.00386	0.00391	CcSEcCtD
Apraclonidine—Myalgia—Docetaxel—head and neck cancer	0.00386	0.00391	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.00383	0.00388	CcSEcCtD
Apraclonidine—Hypersensitivity—Fluorouracil—head and neck cancer	0.00377	0.00383	CcSEcCtD
Apraclonidine—Dry mouth—Docetaxel—head and neck cancer	0.00377	0.00383	CcSEcCtD
Apraclonidine—Oedema—Docetaxel—head and neck cancer	0.0037	0.00375	CcSEcCtD
Apraclonidine—Infection—Docetaxel—head and neck cancer	0.00367	0.00373	CcSEcCtD
Apraclonidine—Nervous system disorder—Docetaxel—head and neck cancer	0.00363	0.00368	CcSEcCtD
Apraclonidine—Pruritus—Fluorouracil—head and neck cancer	0.00362	0.00368	CcSEcCtD
Apraclonidine—Skin disorder—Docetaxel—head and neck cancer	0.00359	0.00364	CcSEcCtD
Apraclonidine—Diarrhoea—Fluorouracil—head and neck cancer	0.0035	0.00355	CcSEcCtD
Apraclonidine—Dizziness—Fluorouracil—head and neck cancer	0.00339	0.00344	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.00337	0.00342	CcSEcCtD
Apraclonidine—Insomnia—Docetaxel—head and neck cancer	0.00334	0.00339	CcSEcCtD
Apraclonidine—Paraesthesia—Docetaxel—head and neck cancer	0.00332	0.00337	CcSEcCtD
Apraclonidine—Dyspnoea—Docetaxel—head and neck cancer	0.0033	0.00334	CcSEcCtD
Apraclonidine—Somnolence—Docetaxel—head and neck cancer	0.00329	0.00333	CcSEcCtD
Apraclonidine—Vomiting—Fluorouracil—head and neck cancer	0.00326	0.0033	CcSEcCtD
Apraclonidine—Dermatitis—Fluorouracil—head and neck cancer	0.00323	0.00327	CcSEcCtD
Apraclonidine—Headache—Fluorouracil—head and neck cancer	0.00321	0.00325	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.00319	0.00324	CcSEcCtD
Apraclonidine—Fatigue—Docetaxel—head and neck cancer	0.00319	0.00323	CcSEcCtD
Apraclonidine—Pain—Docetaxel—head and neck cancer	0.00316	0.00321	CcSEcCtD
Apraclonidine—Constipation—Docetaxel—head and neck cancer	0.00316	0.00321	CcSEcCtD
Apraclonidine—Feeling abnormal—Docetaxel—head and neck cancer	0.00305	0.00309	CcSEcCtD
Apraclonidine—Nausea—Fluorouracil—head and neck cancer	0.00304	0.00309	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Docetaxel—head and neck cancer	0.00302	0.00307	CcSEcCtD
Apraclonidine—Abdominal pain—Docetaxel—head and neck cancer	0.00292	0.00296	CcSEcCtD
Apraclonidine—Hypersensitivity—Docetaxel—head and neck cancer	0.00272	0.00276	CcSEcCtD
Apraclonidine—Asthenia—Docetaxel—head and neck cancer	0.00265	0.00269	CcSEcCtD
Apraclonidine—Pruritus—Docetaxel—head and neck cancer	0.00262	0.00265	CcSEcCtD
Apraclonidine—Diarrhoea—Docetaxel—head and neck cancer	0.00253	0.00257	CcSEcCtD
Apraclonidine—Dizziness—Docetaxel—head and neck cancer	0.00244	0.00248	CcSEcCtD
Apraclonidine—Vomiting—Docetaxel—head and neck cancer	0.00235	0.00238	CcSEcCtD
Apraclonidine—Dermatitis—Docetaxel—head and neck cancer	0.00233	0.00236	CcSEcCtD
Apraclonidine—Headache—Docetaxel—head and neck cancer	0.00232	0.00235	CcSEcCtD
Apraclonidine—Nausea—Docetaxel—head and neck cancer	0.0022	0.00223	CcSEcCtD
